DT PACE + rituximab

DT PACE + rituximab is a combination chemotherapy regimen used primarily in the treatment of multiple myeloma and certain aggressive lymphomas. The standard DT PACE regimen consists of six drugs: dexamethasone (a corticosteroid), thalidomide (an immunomodulatory agent), cisplatin (a platinum-based chemotherapeutic), doxorubicin (an anthracycline antibiotic), cyclophosphamide (an alkylating agent), and etoposide (a topoisomerase II inhibitor)[1][4][5]. Rituximab, a monoclonal antibody targeting CD20 on B cells, is added to this backbone for cases involving CD20-positive malignancies or when additional immunotherapy is indicated. The mechanism of action involves direct cytotoxicity against rapidly dividing cancer cells through DNA damage and inhibition of cell division by the chemotherapeutic agents, immune modulation by thalidomide, and targeted B-cell depletion by rituximab[1][4]. This combination is typically reserved for relapsed/refractory disease or as induction therapy prior to autologous stem cell transplantation.

Other names

dexamethasone thalidomide cisplatin doxorubicin cyclophosphamide etoposide plus rituximab